Today, Embla Medical's CEO Sveinn Sölvason presented the FY 2024 results and achievements. We also touched upon the drivers for the outlook for 2025. In the Q&A session focus was on the potential effects of tariffs and new political landscape in the US.

Embla Medical will release its Q4 2024 interim report on 5 February 2025. The same day at 11.00, the company’s management will present the results and answer questions in an online live event. Besides the financial results, you can get an update on the recent business and regulatory developments.

Dagens aktienyheder med Embla Medical og Spar Nord

Dagens aktienyheder med Spar Nord, Embla Medical, Curasight

With a share price return of +30%, Embla Medical has outperformed both the Danish stock market and the European Medtech sector. Together with Embla Medical’s CEO Sveinn Solvason, we looked back at the main achievements in 2024 and the key drivers behind the results.

Today, Embla Medical's CEO Sveinn Solvason presented and answered questions about the Q3 2024 results, the expectations for the rest of the year, and details about the increased reimbursement on the US market. Changes that creates a large market potential trough access to more advanced solutions for patients.

Embla Medical will release its Q3 2024 interim report on 22 October 2024. The company’s management will present the results in a virtual live event with a Q&A session the next day, 23 October 2024 at 12:30. Besides the financial results, you can get an update on the recent business and regulatory developments.

Dagens aktienyheder med GrønlandsBANKEN, Embla Medical, Ascelia Pharma AB og BioPorto A/S

Dagens aktienyheder 22.10.2024: Bioporto, Inderes, Agillic, Embla, Ascelia Pharma og ExpreS2ion Biotech

Dagens aktienyheder med Embla Medical og GomSpace

Embla Medical var tidligere på ugen repræsenteret af selskabets Head of Investor Relations, Klaus Sindahl, på et HCA investorseminar. Fokus i præsentationen var rettet mod investeringscasen i selskabet med ekstra fokus på de nye tilskudsregler i USA. De nye regler skaber mulighed for flere patienter end tidligere, der kan opnå ret til Embla Medicals mere avancerede Bionics løsninger. Det er noget, som selskabet selv kalder en meningsfuld potentiel langsigtet vækstmulighed.